SCHEMBL13879463

SCHEMBL13879463

CC(C)C1NC(=O)N(c2cc(Cl)cc(Cl)c2)C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
TAS2R8 Q9NYW2 1/20 0.41
TSHR P16473 1/20 0.39
ALDH1A1 P00352 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 2/20 0.34
PARP1 P09874 1/20 0.34
ITGA4 P13612 1/20 0.33
ITGB7 P26010 1/20 0.33
CHRM1 P11229 1/20 0.33
PLA2G10 O15496 1/20 0.33
PLA2G5 P39877 1/20 0.33
BCL2A1 Q16548 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
MMP2 P08253 1/20 0.32
ADAM17 P78536 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879522 0.85 LMNA (0.62) LMNATAS2R8TSHRALDH1A1CYP1A2
SCHEMBL13879457 0.84 LMNA (0.55) LMNATSHRALDH1A1CYP1A2CYP3A4
SCHEMBL11864304 0.84 LMNA (0.39) LMNATAS2R8TSHRALDH1A1HSD17B10
SCHEMBL13879469 0.77 LMNA (0.75) LMNATAS2R8ALDH1A1CYP1A2CYP3A4
SCHEMBL5238330 0.77 TSHR (0.42) TAS2R8TSHRALDH1A1HSD17B10ITGA4
SCHEMBL25069088 0.75 LMNA (0.62) LMNATAS2R8TSHRALDH1A1CYP1A2
SCHEMBL13879428 0.72 LMNA (0.49) LMNATSHRALDH1A1HSD17B10MEN1
SCHEMBL13879476 0.72 LMNA (0.52) LMNATSHRALDH1A1CYP1A2CYP3A4
SCHEMBL8722214 0.72 LMNA (0.72) LMNATSHRALDH1A1MEN1KMT2A
SCHEMBL75285 0.71 LMNA (0.42) LMNATAS2R8ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 LMNA 2024/4885TAS2R8 4662/4885TSHR 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.